Product Description:

BRIGANIX is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Product Features:

Product Name Briganix
Generic Name Brigatinib
Formulation Tablet
Available Pack Size 30’s Pot
Available Strength 90 mg, 180 mg
Registrations Available